{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:06:57Z","timestamp":1791245217915,"version":"4.1.0"},"reference-count":132,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Hematological emergencies are critical medical conditions that require immediate attention due to their rapid progression and life-threatening nature. As various examples, hypercalcemia, often associated with cancers such as multiple myeloma, can lead to severe neurological and cardiac dysfunction. Hyperleukocytosis, common in acute myeloid leukemias, increases the risk of leukostasis and multiorgan failure. Sickle cell crisis, a common complication in sickle cell disease, results from vaso-occlusion, leading to acute pain and tissue ischemia. Tumor lysis syndrome, reported in cases of rapid destruction of cancer cells, causes electrolyte imbalances and acute kidney injury. Acute transfusion reactions, fundamental in hematological conditions, can range from mild allergic responses to severe hemolysis and shock, requiring prompt management. Disseminated intravascular coagulation, involving excessive coagulation and bleeding, is commonly triggered by hematological malignancies, common in the first phases of acute promyelocytic leukemia. Recently, in the era of bispecific antibodies and chimeric antigen receptor T cells, cytokine release syndrome is a manifestation that must be recognized and promptly treated. Understanding the pathophysiology, recognizing the clinical manifestations, and ensuring adequate diagnostic strategies and management approaches for each condition are central to early intervention in improving patient outcomes and reducing mortality.<\/jats:p>","DOI":"10.3390\/jcm13247572","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T10:53:27Z","timestamp":1734000807000},"page":"7572","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Emergencies in Hematology: Why, When and How I Treat?"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9510-4755","authenticated-orcid":false,"given":"Andrea","family":"Duminuco","sequence":"first","affiliation":[{"name":"Hematology Unit with BMT, A.O.U. Policlinico \u201cG.Rodolico-San Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4405-2716","authenticated-orcid":false,"given":"Vittorio","family":"Del Fabro","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Surgery, \u201cKore\u201d University of Enna, 94100 Enna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4079-7899","authenticated-orcid":false,"given":"Paola","family":"De Luca","sequence":"additional","affiliation":[{"name":"Hematology Unit with BMT, A.O.U. Policlinico \u201cG.Rodolico-San Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Leotta","sequence":"additional","affiliation":[{"name":"Hematology Unit with BMT, A.O.U. Policlinico \u201cG.Rodolico-San Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriana Carmela","family":"Limoli","sequence":"additional","affiliation":[{"name":"Hematology Unit with BMT, A.O.U. Policlinico \u201cG.Rodolico-San Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ermelinda","family":"Longo","sequence":"additional","affiliation":[{"name":"Hematology Unit with BMT, A.O.U. Policlinico \u201cG.Rodolico-San Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Nardo","sequence":"additional","affiliation":[{"name":"Hematology Unit with BMT, A.O.U. Policlinico \u201cG.Rodolico-San Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Santuccio","sequence":"additional","affiliation":[{"name":"Hematology Unit with BMT, A.O.U. Policlinico \u201cG.Rodolico-San Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Petronaci","sequence":"additional","affiliation":[{"name":"Hematology Unit with BMT, A.O.U. Policlinico \u201cG.Rodolico-San Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Stanzione","sequence":"additional","affiliation":[{"name":"Hematology Unit with BMT, A.O.U. Policlinico \u201cG.Rodolico-San Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[{"name":"Hematology Unit with BMT, A.O.U. Policlinico \u201cG.Rodolico-San Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1859-6319","authenticated-orcid":false,"given":"Giuseppe Alberto","family":"Palumbo","sequence":"additional","affiliation":[{"name":"Hematology Unit with BMT, A.O.U. Policlinico \u201cG.Rodolico-San Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1055\/a-1049-0647","article-title":"Diagnosis, Pathophysiology and Management of Hypercalcemia in Malignancy: A Review of the Literature","volume":"51","author":"Asonitis","year":"2019","journal-title":"Horm. Metab. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.2022.18331","article-title":"Hypercalcemia: A Review","volume":"328","author":"Walker","year":"2022","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"503","DOI":"10.7861\/clinmed.2023-0227","article-title":"Treatment of Hypercalcaemia of Malignancy in Adults","volume":"23","author":"Donald","year":"2023","journal-title":"Clin. Med."},{"key":"ref_4","unstructured":"Sadiq, N.M., Anastasopoulou, C., Patel, G., and Badireddy, M. (2024). Hypercalcemia, StatPearls."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s12020-017-1353-y","article-title":"Calcium Levels on Admission and before Discharge Are Associated with Mortality Risk in Hospitalized Patients","volume":"57","author":"Akirov","year":"2017","journal-title":"Endocrine"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Gupta, S., Rastogi, A., Singh, P., Chophy, A., Roushan, R., Krishnan, A.S., Joseph, D., Goyal, B., Gupta, A., and Gupta, M. (2023). Treatment Outcomes and Survival in Hypercalcemia of Malignancy: A Grave Metabolic Emergency. Cureus, 15.","DOI":"10.7759\/cureus.35783"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"8962","DOI":"10.1002\/cam4.3594","article-title":"Hypercalcemia Caused by Humoral Effects and Bone Damage Indicate Poor Outcomes in Newly Diagnosed Multiple Myeloma Patients","volume":"9","author":"Bao","year":"2020","journal-title":"Cancer Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jbmr.2022","article-title":"PTHrP Produced by Myeloma Plasma Cells Regulates Their Survival and Pro-Osteoclast Activity For Bone Disease Progression","volume":"29","author":"Cafforio","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 Patients with Newly Diagnosed Multiple Myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1359\/JBMR.040314","article-title":"Macrophage Inflammatory Protein-1\u03b1 Induces Hypercalcemia in Adult T-Cell Leukemia","volume":"19","author":"Okada","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1001\/archsurg.1980.01380060012004","article-title":"Incidence of Hypercalcemia and Malignant Neoplasm","volume":"115","author":"Burt","year":"1980","journal-title":"Arch. Surg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1359\/jbmr.2003.18.3.579","article-title":"Vitamin D-Mediated Hypercalcemia in Lymphoma: Evidence for Hormone Production by Tumor-Adjacent Macrophages","volume":"18","author":"Hewison","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000106100","article-title":"Extensive Bone Marrow Necrosis and Symptomatic Hypercalcemia in B Cell Blastic Transformation of Chronic Myeloid Leukemia: Report of a Case and Review of the Literature","volume":"118","author":"Noguchi","year":"2007","journal-title":"Acta Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3322\/caac.21727","article-title":"Oncologic Emergencies and Urgencies: A Comprehensive Review","volume":"72","author":"Quest","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_15","first-page":"331","article-title":"Denosumab, a RANK Ligand Inhibitor, for the Management of Bone Loss in Cancer Patients","volume":"7","author":"Yee","year":"2012","journal-title":"Clin. Interv. Aging"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Bewersdorf, J.P., and Zeidan, A.M. (2020). Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?. Cells, 9.","DOI":"10.3390\/cells9102310"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"E267","DOI":"10.1188\/17.CJON.E267-E271","article-title":"Leukostasis: Management to Prevent Crisis in Acute Leukemia","volume":"21","author":"Blackburn","year":"2017","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.2147\/IJGM.S321787","article-title":"Leukapheresis and Hyperleukocytosis, Past and Future","volume":"14","author":"Zhang","year":"2021","journal-title":"Int. J. Gen. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Duminuco, A., Nardo, A., Giuffrida, G., Leotta, S., Markovic, U., Giallongo, C., Tibullo, D., Romano, A., Di Raimondo, F., and Palumbo, G.A. (2023). Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future. J. Clin. Med., 12.","DOI":"10.3390\/jcm12062188"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/hon.2292","article-title":"Leukostasis in Adult Acute Hyperleukocytic Leukemia: A Clinician\u2019s Digest","volume":"34","author":"Ali","year":"2016","journal-title":"Hematol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood.V97.7.2121","article-title":"Endothelial Cell Activation by Myeloblasts: Molecular Mechanisms of Leukostasis and Leukemic Cell Dissemination","volume":"97","author":"Stucki","year":"2001","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/j.1537-2995.2007.01406.x","article-title":"Impact of Leukapheresis on Early Death Rate in Adult Acute Myeloid Leukemia Presenting with Hyperleukocytosis","volume":"47","author":"Bug","year":"2007","journal-title":"Transfusion"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1111\/trf.15994","article-title":"Leukapheresis for the Management of Hyperleukocytosis in Acute Myeloid Leukemia-A Systematic Review and Meta-Analysis","volume":"60","author":"Bewersdorf","year":"2020","journal-title":"Transfusion"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Farid, K.M.N., Sauer, T., Schmitt, M., M\u00fcller-Tidow, C., and Schmitt, A. (2023). Symptomatic Patients with Hyperleukocytic FLT3-ITD Mutated Acute Myeloid Leukemia Might Benefit from Leukapheresis. Cancers, 16.","DOI":"10.3390\/cancers16010058"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Duminuco, A., Maugeri, C., Parisi, M., Mauro, E., Fiumara, P.F., Randazzo, V., Salemi, D., Agueli, C., Palumbo, G.A., and Santoro, A. (2022). Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field. Cancers, 14.","DOI":"10.3390\/cancers14092186"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1600-0609.2005.00421.x","article-title":"Grading of Symptoms in Hyperleukocytic Leukaemia: A Clinical Model for the Role of Different Blast Types and Promyelocytes in the Development of Leukostasis Syndrome","volume":"74","author":"Novotny","year":"2005","journal-title":"Eur. J. Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.blre.2012.01.003","article-title":"Hyperleukocytosis, Leukostasis and Leukapheresis: Practice Management","volume":"26","author":"Ganzel","year":"2012","journal-title":"Blood Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1148\/radiology.165.3.3479813","article-title":"Pulmonary Leukostasis: Radiologic-Pathologic Study","volume":"165","author":"Wondergem","year":"1987","journal-title":"Radiology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1038\/s41375-020-0783-3","article-title":"Management of Hyperleukocytosis and Impact of Leukapheresis among Patients with Acute Myeloid Leukemia (AML) on Short- and Long-Term Clinical Outcomes: A Large, Retrospective, Multicenter, International Study","volume":"34","author":"Stahl","year":"2020","journal-title":"Leukemia"},{"key":"ref_30","first-page":"1037","article-title":"Leukapheresis Induced Changes in Cell Cycle Distribution and Nucleoside Transporters in Patients with Untreated Acute Myeloid Leukemia","volume":"5","author":"Powell","year":"1991","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jca.21705","article-title":"Guidelines on the Use of Therapeutic Apheresis in Clinical Practice\u2014Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue","volume":"34","author":"Padmanabhan","year":"2019","journal-title":"J. Clin. Apher."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/bjh.13189","article-title":"Clinical Characteristics and Outcomes in Patients with Acute Promyelocytic Leukaemia and Hyperleucocytosis","volume":"168","author":"Daver","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1182\/bloodadvances.2022007126","article-title":"Characteristics and Outcomes of Patients with Acute Promyelocytic Leukemia and Extreme Hyperleukocytosis at Presentation","volume":"7","author":"Iland","year":"2023","journal-title":"Blood Adv."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","article-title":"Management of Acute Promyelocytic Leukemia: Updated Recommendations from an Expert Panel of the European LeukemiaNet","volume":"133","author":"Sanz","year":"2019","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1182\/blood.V84.11.3843.bloodjournal84113843","article-title":"Early Mortality and the Retinoic Acid Syndrome in Acute Promyelocytic Leukemia: Impact of Leukocytosis, Low-Dose Chemotherapy, PMN\/RAR-Alpha Isoform, and CD13 Expression in Patients Treated with All-Trans Retinoic Acid","volume":"84","author":"Vahdat","year":"1994","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.3109\/10428194.2016.1142083","article-title":"Pre-Treatment with Oral Hydroxyurea Prior to Intensive Chemotherapy Improves Early Survival of Patients with High Hyperleukocytosis in Acute Myeloid Leukemia","volume":"57","author":"Mamez","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1182\/blood-2014-10-551507","article-title":"How I Treat Hyperleukocytosis in Acute Myeloid Leukemia","volume":"125","author":"Ehninger","year":"2015","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1159\/000509934","article-title":"Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress","volume":"45","author":"Malyszko","year":"2020","journal-title":"Kidney Blood Press. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour Lysis Syndrome: New Therapeutic Strategies and Classification","volume":"127","author":"Cairo","year":"2004","journal-title":"Br. J. Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/20009666.2020.1761185","article-title":"Diagnosis and Management of Tumor Lysis Syndrome","volume":"10","author":"Puri","year":"2020","journal-title":"J. Community Hosp. Intern. Med. Perspect."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3324\/haematol.11575","article-title":"Tumor Lysis Syndrome in Patients with Acute Myeloid Leukemia: Identification of Risk Factors and Development of a Predictive Model","volume":"93","author":"Montesinos","year":"2008","journal-title":"Haematologica"},{"key":"ref_42","unstructured":"Adeyinka, A., Kaur, A., and Bashir, K. (2024). Tumor Lysis Syndrome, StatPearls."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ajh.2830470212","article-title":"Acute Spontaneous Tumor Lysis Syndrome","volume":"47","author":"Jasek","year":"1994","journal-title":"Am. J. Hematol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Belay, Y., Yirdaw, K., and Enawgaw, B. (2017). Tumor Lysis Syndrome in Patients with Hematological Malignancies. J. Oncol., 2017.","DOI":"10.1155\/2017\/9684909"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0002-9343(93)90174-N","article-title":"Acute Tumor Lysis Syndrome in Patients with High-Grade Non-Hodgkin\u2019s Lymphoma","volume":"94","author":"Hande","year":"1993","journal-title":"Am. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.V120.21.238.238","article-title":"Incidence of Treatment-Related, Laboratory and Clinical Tumor Lysis Syndrome","volume":"120","author":"Cairo","year":"2012","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/1042819021000054661","article-title":"Incidence, Medical Resource Utilisation and Costs of Hyperuricemia and Tumour Lysis Syndrome in Patients with Acute Leukaemia and Non-Hodgkin\u2019s Lymphoma in Four European Countries","volume":"44","author":"Annemans","year":"2003","journal-title":"Leuk. Lymphoma"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1200\/JCO.2009.26.8896","article-title":"Control of Plasma Uric Acid in Adults at Risk for Tumor Lysis Syndrome: Efficacy and Safety of Rasburicase Alone and Rasburicase Followed by Allopurinol Compared with Allopurinol Alone--Results of a Multicenter Phase III Study","volume":"28","author":"Cortes","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/annonc\/mdv317","article-title":"FLORENCE: A Randomized, Double-Blind, Phase III Pivotal Study of Febuxostat versus Allopurinol for the Prevention of Tumor Lysis Syndrome (TLS) in Patients with Hematologic Malignancies at Intermediate to High TLS Risk","volume":"26","author":"Spina","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1681\/ASN.2005050572","article-title":"Uric Acid-Induced C-Reactive Protein Expression: Implication on Cell Proliferation and Nitric Oxide Production of Human Vascular Cells","volume":"16","author":"Kang","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1001\/jama.1978.03280500068025","article-title":"Hyperphosphatemia, Hypocalcemia, and Transient Renal Failure. Results of Cytotoxic Treatment of Acute Lymphoblastic Leukemia","volume":"239","author":"Ettinger","year":"1978","journal-title":"JAMA"},{"key":"ref_52","unstructured":"Goyal, A., Anastasopoulou, C., Ngu, M., and Singh, S. (2023). Hypocalcemia. Endocrinology and Diabetes: A Problem Oriented Approach, Springer. [2nd ed.]."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bjh.13403","article-title":"Guidelines for the Management of Tumour Lysis Syndrome in Adults and Children with Haematological Malignancies on Behalf of the British Committee for Standards in Haematology","volume":"169","author":"Jones","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jemermed.2019.08.009","article-title":"Oncologic Emergencies: The Fever With Too Few Neutrophils","volume":"57","author":"Long","year":"2019","journal-title":"J. Emerg. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/cid\/cir492","article-title":"Infections in Patients with Hematologic Neoplasms and Hematopoietic Stem Cell Transplantation: Neutropenia, Humoral, and Splenic Defects","volume":"53","author":"Safdar","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Duminuco, A., Scarso, S., Cupri, A., Parrinello, N.L., Villari, L., Scuderi, G., Giunta, G., Leotta, S., Milone, G.A., and Giuffrida, G. (2023). Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients. J. Clin. Med., 12.","DOI":"10.3390\/jcm12020578"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Palumbo, G.A., Cambria, D., La Spina, E., Duminuco, A., Laneri, A., Longo, A., Vetro, C., Giallongo, S., Romano, A., and Di Raimondo, F. (2023). Ruxolitinib Treatment in Myelofibrosis and Polycythemia Vera Causes Suboptimal Humoral Immune Response Following Standard and Booster Vaccination with BNT162b2 MRNA COVID-19 Vaccine. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1117815"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Duminuco, A., Romano, A., Leotta, D., La Spina, E., Cambria, D., Bulla, A., Del Fabro, V., Tibullo, D., Giallongo, C., and Palumbo, G.A. (2023). Clinical Outcome of SARS-CoV-2 Infections Occurring in Multiple Myeloma Patients after Vaccination and Prophylaxis with Tixagevimab\/Cilgavimab. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1157610"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/cncr.35005","article-title":"Efficacy and Safety of Tixagevimab-Cilgavimab versus SARS-CoV-2 Breakthrough Infection in the Hematological Conditions","volume":"130","author":"Duminuco","year":"2024","journal-title":"Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Guarino, M., Perna, B., Cesaro, A.E., Maritati, M., Spampinato, M.D., Contini, C., and De Giorgio, R. (2023). 2023 Update on Sepsis and Septic Shock in Adult Patients: Management in the Emergency Department. J. Clin. Med., 12.","DOI":"10.3390\/jcm12093188"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Keck, J.M., Wingler, M.J.B., Cretella, D.A., Vijayvargiya, P., Wagner, J.L., Barber, K.E., Jhaveri, T.A., and Stover, K.R. (2022). Approach to Fever in Patients with Neutropenia: A Review of Diagnosis and Management. Ther. Adv. Infect. Dis., 9.","DOI":"10.1177\/20499361221138346"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Chan, C.W., Molassiotis, A., and Lee, H.K.K. (2023). Clinical and Microbiological Profiles in Post-Chemotherapy Neutropenic Fever in Hematological Malignancy: Exploration of Clinical Phenotype Patterns by Two-Step Cluster Analysis. BMC Infect. Dis., 23.","DOI":"10.1186\/s12879-023-08218-8"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4103\/0974-2727.163126","article-title":"Febrile Neutropenia in Hematological Malignancies: Clinical and Microbiological Profile and Outcome in High Risk Patients","volume":"7","author":"Lakshmaiah","year":"2015","journal-title":"J. Lab. Physicians"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/hematolrep14020011","article-title":"Saprochete Capitata: Emerging Infections from Uncommon Microorganisms in Hematological Diseases","volume":"14","author":"Duminuco","year":"2022","journal-title":"Hematol. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"\u0141anocha, A., \u0141anocha-Arendarczyk, N., Wilczy\u0144ska, D., Zdziarska, B., and Kosik-Bogacka, D. (2022). Protozoan Intestinal Parasitic Infection in Patients with Hematological Malignancies. J. Clin. Med., 11.","DOI":"10.3390\/jcm11102847"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"9329","DOI":"10.4081\/hr.2021.9329","article-title":"Therapeutic Innovation for Multi-Resistant Candidemics: Synergy of Isavuconazole and Caspofungin Association","volume":"13","author":"Duminuco","year":"2021","journal-title":"Hematol. Rep."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Massey, E.J., Davenport, R.D., and Kaufman, R.M. (2023). Hemolytic Transfusion Reaction. Practical Transfusion Medicine, Wiley-Blackwell. [6th ed.].","DOI":"10.1002\/9781119665885.ch8"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000492950","article-title":"The Pathogenic Involvement of Neutrophils in Acute Respiratory Distress Syndrome and Transfusion-Related Acute Lung Injury","volume":"45","author":"Rebetz","year":"2018","journal-title":"Transfus. Med. Hemother."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2018-10-860809","article-title":"Transfusion-Associated Circulatory Overload and Transfusion-Related Acute Lung Injury","volume":"133","author":"Semple","year":"2019","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1046\/j.1537-2995.2001.41121493.x","article-title":"Transfusion-Transmitted Bacterial Infection in the United States, 1998 through 2000","volume":"41","author":"Kuehnert","year":"2001","journal-title":"Transfusion"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.emc.2018.04.009","article-title":"Emergency Medicine Evaluation and Management of Anemia","volume":"36","author":"Long","year":"2018","journal-title":"Emerg. Med. Clin. N. AM."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/01.NAJ.0000532808.81713.fc","article-title":"CE: A Review of Current Practice in Transfusion Therapy","volume":"118","author":"Carman","year":"2018","journal-title":"Am. J. Nurs."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1055\/s-0042-1756300","article-title":"Disseminated Intravascular Coagulation: The Past, Present, and Future Considerations","volume":"48","author":"Iba","year":"2022","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1111\/jth.15074","article-title":"Management of Hemostatic Complications in Acute Leukemia: Guidance from the SSC of the ISTH","volume":"18","author":"Wang","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"102393","DOI":"10.1016\/j.bcmd.2019.102393","article-title":"Coagulopathy in Cytogenetically and Molecularly Distinct Acute Leukemias at Diagnosis: Comprehensive Study","volume":"81","author":"Guo","year":"2020","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/CCO.0000000000000402","article-title":"Thrombosis in Adult Patients with Acute Leukemia","volume":"29","author":"Venditti","year":"2017","journal-title":"Curr. Opin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1055\/s-0039-1693478","article-title":"The Role of Abnormal Hemostasis and Fibrinolysis in Morbidity and Mortality of Acute Promyelocytic Leukemia","volume":"45","author":"Kwaan","year":"2019","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"8S","DOI":"10.1177\/1076029618806424","article-title":"Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies","volume":"24","author":"Papageorgiou","year":"2018","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Zanoli, L., Ozturk, K., Cappello, M., Inserra, G., Geraci, G., Tuttolomondo, A., Torres, D., Pinto, A., Duminuco, A., and Riguccio, G. (2019). Inflammation and Aortic Pulse Wave Velocity: A Multicenter Longitudinal Study in Patients with Inflammatory Bowel Disease. J. Am. Heart Assoc., 8.","DOI":"10.1161\/JAHA.118.010942"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Milone, G., Bellofiore, C., Leotta, S., Milone, G.A., Cupri, A., Duminuco, A., Garibaldi, B., and Palumbo, G. (2022). Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology. J. Clin. Med., 11.","DOI":"10.3390\/jcm11030623"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1055\/s-0037-1616068","article-title":"Towards Definition, Clinical and Laboratory Criteria, and a Scoring System for Disseminated Intravascular Coagulation","volume":"86","author":"Taylor","year":"2001","journal-title":"Thromb. Haemost."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1600-0609.2006.00711.x","article-title":"Disseminated Intravascular Coagulation in Acute Leukemia: Clinical and Laboratory Features at Presentation","volume":"77","author":"Yanada","year":"2006","journal-title":"Eur. J. Haematol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/01.CCM.0000202209.42491.38","article-title":"A Multicenter, Prospective Validation of Disseminated Intravascular Coagulation Diagnostic Criteria for Critically Ill Patients: Comparing Current Criteria","volume":"34","author":"Gando","year":"2006","journal-title":"Crit. Care Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2141.2009.07600.x","article-title":"Guidelines for the Diagnosis and Management of Disseminated Intravascular Coagulation. British Committee for Standards in Haematology","volume":"145","author":"Levi","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.thromres.2009.08.017","article-title":"Expert Consensus for the Treatment of Disseminated Intravascular Coagulation in Japan","volume":"125","author":"Wada","year":"2010","journal-title":"Thromb. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.thromres.2011.08.028","article-title":"Italian Society for Thrombosis and Haemostasis Diagnosis and Treatment of Disseminated Intravascular Coagulation: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)","volume":"129","author":"Baudo","year":"2012","journal-title":"Thromb. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/jth.12155","article-title":"Guidance for Diagnosis and Treatment of DIC from Harmonization of the Recommendations from Three Guidelines","volume":"11","author":"Wada","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/j.1538-7836.2004.00787.x","article-title":"Effects of All-Trans Retinoic Acid or Chemotherapy on the Molecular Regulation of Systemic Blood Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia","volume":"2","author":"Tallman","year":"2004","journal-title":"J. Thromb. Haemost."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/0049-3848(93)90109-2","article-title":"Clinical Evaluation of Low-Molecular-Weight Heparin (FR-860) on Disseminated Intravascular Coagulation (DIC)--a Multicenter Co-Operative Double-Blind Trial in Comparison with Heparin","volume":"72","author":"Sakuragawa","year":"1993","journal-title":"Thromb. Res."},{"key":"ref_91","first-page":"328","article-title":"Thromboembolism Prophylaxis in Adult Patients with Acute Lymphoblastic Leukemia Treated in the GRAALL-2005 Study","volume":"136","author":"Orvain","year":"2020","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic Thrombocytopenic Purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2011.051433","article-title":"Evidence for a Role of Anti-ADAMTS13 Autoantibodies despite Normal ADAMTS13 Activity in Recurrent Thrombotic Thrombocytopenic Purpura","volume":"97","author":"George","year":"2012","journal-title":"Haematologica"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.3324\/haematol.2022.280702","article-title":"Di Relapse of Immune-Mediated Thrombotic Thrombocytopenic Purpura Following MRNA COVID-19 Vaccination: A Prospective Cohort Study","volume":"107","author":"Giuffrida","year":"2022","journal-title":"Haematologica"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the Diagnosis and Management of Thrombotic Thrombocytopenic Purpura and Other Thrombotic Microangiopathies","volume":"158","author":"Scully","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/ajh.24339","article-title":"Long-Term Outcomes of Thrombotic Microangiopathy Treated with Plasma Exchange: A Systematic Review","volume":"91","author":"Thejeel","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Khurana, K., Mahajan, S., Acharya, S., Kumar, S., and Toshniwal, S. (2024). Clinical Biomarkers of Acute Vaso-Occlusive Sickle Cell Crisis. Cureus, 16.","DOI":"10.7759\/cureus.56389"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/ejh.13430","article-title":"The Vaso-Occlusive Pain Crisis in Sickle Cell Disease: Definition, Pathophysiology, and Management","volume":"105","author":"Darbari","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1097\/MS9.0000000000000696","article-title":"Tackling Sickle Cell Crisis in Nigeria: The Need for Newer Therapeutic Solutions in Sickle Cell Crisis Management\u2014Short Communication","volume":"85","author":"Nnagha","year":"2023","journal-title":"Ann. Med. Surg."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.hoc.2016.01.011","article-title":"Management of Patients with Sickle Cell Disease Using Transfusion Therapy: Guidelines and Complications","volume":"30","author":"Chou","year":"2016","journal-title":"Hematol. Oncol. Clin. N. AM."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.1097\/MS9.0000000000002478","article-title":"CRISPR\/Cas9 in the Treatment of Sickle Cell Disease (SCD) and Its Comparison with Traditional Treatment Approaches: A Review","volume":"86","author":"Tariq","year":"2024","journal-title":"Ann. Med. Surg."},{"key":"ref_104","unstructured":"Bradshaw, H., and Woolridge, D. (2024). Sickle Cell Crisis. Emergency Department Analgesia: An Evidence-Based Guide, Cambridge University Press."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.chest.2015.12.016","article-title":"Crises in Sickle Cell Disease","volume":"149","author":"Novelli","year":"2015","journal-title":"Chest"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14740\/jocmr4841","article-title":"Improving the Emergency Department Management of Sickle Cell Vaso-Occlusive Pain Crisis: The Role and Options of Sublingual and Intranasally Administered Analgesia","volume":"15","author":"Ojo","year":"2023","journal-title":"J. Clin. Med. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/1076029609352661","article-title":"Review: Management of Painful Vaso-Occlusive Crisis of Sickle-Cell Anemia: Consensus Opinion","volume":"16","author":"Mousa","year":"2010","journal-title":"Clin. Appl. Thromb.\/Hemost."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/AJP.0000000000000036","article-title":"A Retrospective Review of Acupuncture Use for the Treatment of Pain in Sickle Cell Disease Patients: Descriptive Analysis from a Single Institution","volume":"30","author":"Lu","year":"2014","journal-title":"Clin. J. Pain"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/MOH.0b013e32834521dd","article-title":"Hydroxyurea for Sickle Cell Anemia: What Have We Learned and What Questions Still Remain?","volume":"18","author":"McGann","year":"2011","journal-title":"Curr. Opin. Hematol."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Mitra, A., Barua, A., Huang, L., Ganguly, S., Feng, Q., and He, B. (2023). From Bench to Bedside: The History and Progress of CAR T Cell Therapy. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1188049"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1007\/s00277-024-05725-9","article-title":"Impact of Minimal Residual Disease Response and of Status of Disease on Survival after Blinatumomab in B-Cell Acute Lymphoblastic Leukemia: Results from a Real-Life Study","volume":"103","author":"Leotta","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The Present and Future of Bispecific Antibodies for Cancer Therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Duminuco, A., Markovic, U., Parrinello, N.L., Lo Nigro, L., Mauro, E., Vetro, C., Parisi, M., Maugeri, C., Fiumara, P.F., and Milone, G. (2023). Potential Clinical Impact of T-Cell Lymphocyte Kinetics Monitoring in Patients with B Cell Precursors Acute Lymphoblastic Leukemia Treated with Blinatumomab: A Single-Center Experience. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1195734"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine Release Syndrome","volume":"6","author":"Subklewe","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine Release Syndrome and Associated Neurotoxicity in Cancer Immunotherapy","volume":"22","author":"Morris","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_116","first-page":"16","article-title":"Central Nervous System Manifestations in Acute and Chronic Graft-versus-Host Disease","volume":"139","author":"Lambert","year":"2024","journal-title":"Brain"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Yan, Z., Zhang, H., Cao, J., Zhang, C., Liu, H., Huang, H., Cheng, H., Qiao, J., Wang, Y., and Wang, Y. (2021). Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.611366"},{"key":"ref_119","first-page":"294","article-title":"Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review","volume":"28","author":"Grant","year":"2022","journal-title":"Transpl. Transplant. Cell Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1016\/j.bbmt.2020.07.031","article-title":"Identification of Neurotoxicity after Chimeric Antigen Receptor (CAR) T Cell Infusion without Deterioration in the Immune Effector Cell-Associated Encephalopathy (ICE) Score","volume":"26","author":"Herr","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Y\u00e1\u00f1ez, L., Alarc\u00f3n, A., S\u00e1nchez-Escamilla, M., and Perales, M.A. (2020). How I Treat Adverse Effects of CAR-T Cell Therapy. ESMO Open, 4.","DOI":"10.1136\/esmoopen-2020-000746"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s11899-023-00702-x","article-title":"A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases","volume":"18","author":"Duminuco","year":"2023","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2147\/BLCTT.S409443","article-title":"Polycythemia Vera: Barriers to and Strategies for Optimal Management","volume":"13","author":"Duminuco","year":"2023","journal-title":"Blood Lymphat. Cancer"},{"key":"ref_124","first-page":"2430","article-title":"How I Treat Refractory CRS and ICANS after CAR T-Cell Therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Gozzo, L., Leotta, S., Romano, G.L., Vetro, C., Duminuco, A., Milone, G., Cupri, A., Palumbo, F.E., Brancati, S., and Ruscica, R. (2024). Early Access for Medicines in ITALY: The Case of Ruxolitinib for Patients with Graft-Versus-Host Disease. J. Clin. Med., 13.","DOI":"10.3390\/jcm13144273"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1080\/14656566.2023.2228695","article-title":"The Pharmacotherapeutic Management of Patients with Myelofibrosis: Looking beyond JAK Inhibitors","volume":"24","author":"Duminuco","year":"2023","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Duminuco, A., Chifotides, H.T., Giallongo, S., Giallongo, C., Tibullo, D., and Palumbo, G.A. (2023). ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis. Cancers, 16.","DOI":"10.3390\/cancers16010154"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"E119","DOI":"10.1002\/ajh.24726","article-title":"Adrenal Insufficiency: An Emerging Challenge in Thalassemia?","volume":"92","author":"Baldini","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"258","DOI":"10.7861\/clinmedicine.17-3-258","article-title":"Adrenal Insufficiency\u2014Recognition and Management","volume":"17","author":"Pazderska","year":"2017","journal-title":"Clin. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"371","DOI":"10.7861\/clinmed.2019-0324","article-title":"Guidance for the Prevention and Emergency Management of Adult Patients with Adrenal Insufficiency","volume":"20","author":"Simpson","year":"2020","journal-title":"Clin. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.amjmed.2005.01.026","article-title":"Anemia and Ischemia: Myocardial Injury in Patients with Gastrointestinal Bleeding","volume":"118","author":"Bellotto","year":"2005","journal-title":"Am. J. Med."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Duminuco, A., Au Yeung, J., Vaghela, R., Virdee, S., Woodley, C., Asirvatham, S., Curto-Garcia, N., Sriskandarajah, P., O\u2019Sullivan, J., and de Lavallade, H. (2024). Development of a Natural Language Processing Pipeline for Assessment of Cardiovascular Risk in Myeloproliferative Neoplasms. Hemasphere, 8.","DOI":"10.1002\/hem3.143"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/24\/7572\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:53:47Z","timestamp":1760115227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/24\/7572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":132,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["jcm13247572"],"URL":"https:\/\/doi.org\/10.3390\/jcm13247572","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,12]]}}}